Search research articles
Contact Us
Filters
Showing results (101-110 of 124) with videos related to
Page
of 13
Sort By:
ESMO Open
|
August 22, 2024
Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI
A H S Alig, D P Modest, S Stintzing, et al.
Proteomics
|
June 3, 2010
Peptidomic profiling of human cerebrospinal fluid identifies YPRPIHPA as a novel substrate for prolylcarboxypeptidase
Xuemei Zhao, Katie Southwick, Helene L Cardasis, et al.
ESMO Open
|
June 4, 2023
S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma-final results of the randomized AIO MATEO phase II trial
G Stocker, S Lorenzen, T Ettrich, et al.
The Journal of Clinical Endocrinology and Metabolism
|
January 1, 1996
Molecular genetics and pathophysiology of 17 beta-hydroxysteroid dehydrogenase 3 deficiency
S Andersson, W M Geissler, L Wu, et al.
Zeitschrift Fur Gastroenterologie
|
March 10, 2009
[Gastrointestinal oncology - therapy update 2008 / 2009]
M P Ebert, C Auernhammer, K Caca, et al.
Acta Crystallographica. Section F, Structural Biology and Crystallization Communications
|
June 3, 2010
Expression, purification and crystallization of human prolylcarboxypeptidase
Pravien D Abeywickrema, Sangita B Patel, Noel J Byrne, et al.
Journal of Medicinal Chemistry
|
September 23, 2010
Design and synthesis of prolylcarboxypeptidase (PrCP) inhibitors to validate PrCP as a potential target for obesity
Changyou Zhou, Margareta Garcia-Calvo, Shirly Pinto, et al.
Journal of Medicinal Chemistry
|
February 13, 2016
Definitive Metabolite Identification Coupled with Automated Ligand Identification System (ALIS) Technology: A Novel Approach to Uncover Structure-Activity Relationships and Guide Drug Design in a Factor IXa Inhibitor Program
Ting Zhang, Yong Liu, Xianshu Yang, et al.
Journal of Cancer Research and Clinical Oncology
|
May 26, 2020
Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109)
A Kurreck, M Geissler, U M Martens, et al.
British Journal of Cancer
|
November 22, 2012
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104
S Boeck, A Jung, R P Laubender, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 124) with videos related to
Sort By:
Page
of 13
ESMO Open
|
August 22, 2024
Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI
A H S Alig, D P Modest, S Stintzing, et al.
Proteomics
|
June 3, 2010
Peptidomic profiling of human cerebrospinal fluid identifies YPRPIHPA as a novel substrate for prolylcarboxypeptidase
Xuemei Zhao, Katie Southwick, Helene L Cardasis, et al.
ESMO Open
|
June 4, 2023
S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma-final results of the randomized AIO MATEO phase II trial
G Stocker, S Lorenzen, T Ettrich, et al.
The Journal of Clinical Endocrinology and Metabolism
|
January 1, 1996
Molecular genetics and pathophysiology of 17 beta-hydroxysteroid dehydrogenase 3 deficiency
S Andersson, W M Geissler, L Wu, et al.
Zeitschrift Fur Gastroenterologie
|
March 10, 2009
[Gastrointestinal oncology - therapy update 2008 / 2009]
M P Ebert, C Auernhammer, K Caca, et al.
Acta Crystallographica. Section F, Structural Biology and Crystallization Communications
|
June 3, 2010
Expression, purification and crystallization of human prolylcarboxypeptidase
Pravien D Abeywickrema, Sangita B Patel, Noel J Byrne, et al.
Journal of Medicinal Chemistry
|
September 23, 2010
Design and synthesis of prolylcarboxypeptidase (PrCP) inhibitors to validate PrCP as a potential target for obesity
Changyou Zhou, Margareta Garcia-Calvo, Shirly Pinto, et al.
Journal of Medicinal Chemistry
|
February 13, 2016
Definitive Metabolite Identification Coupled with Automated Ligand Identification System (ALIS) Technology: A Novel Approach to Uncover Structure-Activity Relationships and Guide Drug Design in a Factor IXa Inhibitor Program
Ting Zhang, Yong Liu, Xianshu Yang, et al.
Journal of Cancer Research and Clinical Oncology
|
May 26, 2020
Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109)
A Kurreck, M Geissler, U M Martens, et al.
British Journal of Cancer
|
November 22, 2012
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104
S Boeck, A Jung, R P Laubender, et al.
Page
of 13